Implementation of Academic Detailing Interventions on Prescribing of Antimicrobial Drugs in Primary Health Care
NCT05090475 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16
Last updated 2024-01-02
Summary
World increase in mortality from consequences of antimicrobial resistance (AMR) represents a significant public health problem. Irrational prescribing of antimicrobial drugs (AMD) in general population is one of the main causes of development AMR. This is also contributed by fact that up to 90% of total antimicrobial consumption in Europe is related to the general population. Problem of AMR has been recognized by World Health Organization and Council of European Union, which support the establishment of the antimicrobial stewardship team (A-team). A-team provides co-ordinated interventions that promote rational use of AMD. To date, no study has been carried out in which A-team from hospital environment goes to primary health care for the purpose of rationalization prescribing of AMD by primary health care practitioners. Project for implementation of hospital A-team in primary health care in Koprivnica-Križevci County was initiated using academic detailing method aimed at rationalization of the consumption of AMD.
Conditions
- Upper Respiratory Tract Infections
- Acute Respiratory Tract Infection
- Viral Infection
Interventions
- BEHAVIORAL
-
Academic detailing intervention
Academic detailing or educational outreach is a method based on scientific data with the help of educated A-team members in the form of direct (face-to-face) interactions, prescribing practices change and adherence improves according to the application of currently valid therapeutic guidelines
Sponsors & Collaborators
-
Koprivnica Križevci County
collaborator UNKNOWN -
Interdisciplinary section for the control of antibiotic resistance (ISKRA)
collaborator UNKNOWN -
General Hospital Koprivnica
lead OTHER
Principal Investigators
-
Darija Kuruc Poje · General Hospital Koprivnica
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 25 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-04-01
- Primary Completion
- 2020-04-30
- Completion
- 2022-12-31
Countries
- Croatia
Study Locations
More Related Trials
-
Delayed Antibiotic Therapy in General Practice
NCT05361239 ·Status: COMPLETED
-
Telephone-Based Re-education for Hp Eradication
NCT03193450 ·Status: COMPLETED ·Phase: NA
-
Helicobacter Pylori Resistance
NCT05019586 ·Status: COMPLETED
-
Real-world Treatment of H. Pylori Eradication in Patients with Comorbidity
NCT05475431 ·Status: COMPLETED
-
PK of Levofloxacin in MDR-TB Patients
NCT03000517 ·Status: COMPLETED
-
The Impact of Antibiotics MIC Value on the Efficacy of Treatment Regimens for Helicobacter Pylori Infection.
NCT03583476 ·Status: UNKNOWN
-
Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori
NCT06751121 ·Status: COMPLETED ·Phase: PHASE3
-
Community-based Helicobacter Pylori Eradication
NCT00155389 ·Status: UNKNOWN ·Phase: PHASE4
-
Dexlansoprazole MR-Based Concomitant Quadruple Therapy
NCT03829150 ·Status: COMPLETED ·Phase: NA
-
Israeli Judicious Antibiotic Prescription Study
NCT01187758 ·Status: COMPLETED ·Phase: NA
-
Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment
NCT03139253 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study on Eradication Rate of Triple Therapy According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients
NCT03099876 ·Status: UNKNOWN
-
Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy
NCT01537055 ·Status: UNKNOWN ·Phase: PHASE4
-
Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia
NCT00035347 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication
NCT01163435 ·Status: COMPLETED ·Phase: PHASE4
-
Meropenem Dosage Strategy Based on PPK Model
NCT01944319 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers
NCT01495065 ·Status: TERMINATED ·Phase: PHASE1
-
PA Tolerability, Safety and Pharmacokinetics in Healthy Volunteers
NCT04174937 ·Status: COMPLETED ·Phase: PHASE1
-
High-Dose Dual Therapy for H. Pylori Eradication (RETRO-HP Study)
NCT07121205 ·Status: COMPLETED
-
Helicobacter Pylori Infection and Gastric Diseases in Lao PDR: First Community-Wide Population-Based Study
NCT07340593 ·Status: COMPLETED
-
Synergistic Effect of Plasmid Inhibitors and Antimicrobial Drugs Against Clinical MDR-hvKP
NCT05932355 ·Status: UNKNOWN
-
Reducing Antibiotic Use by Implementation of Stewardship in Primary and Urgent Care
NCT07217002 ·Status: ACTIVE_NOT_RECRUITING
-
Epidemiology of Antimicrobial-use and Antimicrobial-resistant Infections in Four Hospitals in Thailand
NCT07082465 ·Status: NOT_YET_RECRUITING
-
Efficacy and Safety of 14-day Concomitant Therapy for Refractory Helicobacter Pylori Infection
NCT05133193 ·Status: UNKNOWN ·Phase: NA
-
Molecular Detection of Antibiotic Resistance and H Pylori Eradication
NCT01168063 ·Status: COMPLETED ·Phase: NA